Furthermore, CD30 CAR-T cells have been evaluated in clinical trials for the treatment of r/r Hodgkin lymphoma and anaplastic large cell lymphoma patients, showing good tolerability but modest efficacy [128, 129]. Here, TNFRSF8 is linked to anaplastic large cell lymphoma.